Subbiah, Vivek <br/><br/>
Treatment of patients with advanced neurofibromatosis type 2 with novel molecularly targeted therapies: from bench to bedside.  [electronic resource] 

 -  Journal of clinical oncology : official journal of the American Society of Clinical Oncology  Feb 2012 
 - e64-8 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural 
<br/><br/><label>ISSN: </label>1527-7755 
<br/><br/><label>Standard No.: </label>10.1200/JCO.2011.38.2614  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Angiogenesis Inhibitors--therapeutic use<br/>Antibodies, Monoclonal, Humanized--administration & dosage<br/>Antineoplastic Agents--adverse effects<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Benzenesulfonates--administration & dosage<br/>Bevacizumab<br/>Child<br/>Child, Preschool<br/>Drug Synergism<br/>Erlotinib Hydrochloride<br/>Female<br/>Humans<br/>Indoles--administration & dosage<br/>Male<br/>Molecular Targeted Therapy--methods<br/>Neurofibromatosis 2--drug therapy<br/>Niacinamide--analogs & derivatives<br/>Phenylurea Compounds<br/>Pyridines--administration & dosage<br/>Pyrroles--administration & dosage<br/>Quinazolines--administration & dosage<br/>Sirolimus--administration & dosage<br/>Sorafenib<br/>Sunitinib<br/>TOR Serine-Threonine Kinases--antagonists & inhibitors<br/>Treatment Outcome<br/>Valproic Acid--administration & dosage<br/>Vascular Endothelial Growth Factor A--antagonists & inhibitors<br/>Young Adult